207 related articles for article (PubMed ID: 3896483)
1. Ifosfamide--pharmacology, safety and therapeutic potential.
Brade WP; Herdrich K; Varini M
Cancer Treat Rev; 1985 Mar; 12(1):1-47. PubMed ID: 3896483
[No Abstract] [Full Text] [Related]
2. Ifosfamide: European perspective.
Burkert H
Semin Oncol; 1982 Dec; 9(4 Suppl 1):28-35. PubMed ID: 6761866
[No Abstract] [Full Text] [Related]
3. The anticancer spectrum of ifosfamide.
Hunter HL; Harrison EF
Semin Oncol; 1982 Dec; 9(4 Suppl 1):96-100. PubMed ID: 6761868
[No Abstract] [Full Text] [Related]
4. Ifosfamide.
Zalupski M; Baker LH
J Natl Cancer Inst; 1988 Jun; 80(8):556-66. PubMed ID: 3286879
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide vs cyclophosphamide in cancer therapy.
Weiss RB
Oncology (Williston Park); 1991 May; 5(5):67-76; discussion 76-82, 84-6. PubMed ID: 1653004
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
Schnitker J; Brock N; Burkert H; Fichtner E
Arzneimittelforschung; 1976; 26(10):1783-92. PubMed ID: 798586
[TBL] [Abstract][Full Text] [Related]
7. [Clinical experience with the cytostatic drug ifosfamide].
Ritter S; Schröder HJ
Med Welt; 1977 Sep; 28(35):1395-1400. PubMed ID: 70737
[No Abstract] [Full Text] [Related]
8. Ifosfamide: an old drug recently rediscovered.
Cavalli F
Eur J Cancer Clin Oncol; 1988 Jun; 24(6):959-61. PubMed ID: 3409945
[No Abstract] [Full Text] [Related]
9. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
Hoefer H; Scheef W; Titscher R; Kokron O
Osterr Z Onkol; 1974; (1):3-7. PubMed ID: 4619650
[No Abstract] [Full Text] [Related]
11. Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects.
Greco C; Corsi A; Caputo M; Cavallari A; Calabresi F
Tumori; 1979 Apr; 65(2):169-80. PubMed ID: 462569
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide in experimental tumor systems.
Goldin A
Semin Oncol; 1982 Dec; 9(4 Suppl 1):14-23. PubMed ID: 6761864
[No Abstract] [Full Text] [Related]
13. Comparative effects of cyclophosphamide and isophosphamide on Lewis lung carcinoma.
Corsi A; Calabresi F; Greco C
Br J Cancer; 1978 Nov; 38(5):631-3. PubMed ID: 728352
[No Abstract] [Full Text] [Related]
14. Ifosfamide in paediatric oncology: tried but not tested?
Shaw PJ; Eden T
Lancet; 1990 Apr; 335(8696):1022-3. PubMed ID: 1970073
[No Abstract] [Full Text] [Related]
15. Comparative activity of ifosfamide and cyclophosphamide.
Brade W; Seeber S; Herdrich K
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S1-9. PubMed ID: 3545522
[TBL] [Abstract][Full Text] [Related]
16. Use and safety of high-dose ifosfamide.
Holoye PY; Anderson T; Duelge J; Hansen RM; Ritch PS
Semin Oncol; 1982 Dec; 9(4 Suppl 1):78-86. PubMed ID: 6298946
[No Abstract] [Full Text] [Related]
17. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.
Berger DP; Fiebig HH; Winterhalter BR; Wallbrecher E; Henss H
Cancer Chemother Pharmacol; 1990; 26 Suppl():S7-11. PubMed ID: 2347054
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates.
Kuśnierczyk H; Radzikowski C; Paprocka M; Budzyński W; Rak J; Kinas R; Misiura K; Stec W
J Immunopharmacol; 1986; 8(4):455-80. PubMed ID: 3805744
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
Prescrire Int; 1998 Apr; 7(34):45-7. PubMed ID: 10183382
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
Paprocka M; Kuśnierczyk H; Budzyński W; Rak J; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1986; 34(3):275-84. PubMed ID: 3592931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
